CRP and histiocytic sarcoma: This also explains why there was not a significant difference between groups in the decrease of the CRP levels from admission to 24 h of HS nor from admission to 48 h afterwards; this can be attributed to the latency in the onset of tocilizumab’s effect after its administration.